Products for Research Use Only
RegisterLogin

Vandetanib-d4

CAT: 0804-HY-10260S1-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10260S1-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM) . Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) [1][2].
CAS Number
1215100-18-7
UNSPSC
12352005
Target
Apoptosis; Autophagy; Isotope-Labeled Compounds; VEGFR
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Autophagy; Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
N(C=1C2=C(C=C(OCC3CC(N(C)C(C3)([2H])[2H])([2H])[2H])C(OC)=C2)N=CN1)C4=C(F)C=C(Br)C=C4
Molecular Formula
C22H20D4BrFN4O2
Molecular Weight
479.38
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62 (16) :4645-55.|[3]Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012 Aug 1;84 (3) :260-7.|[4]Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res. 2013 Feb 15;319 (4) :417-23.|[5]Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res. 2012 Jul 15;18 (14) :3924-33.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10260-01Vandetanib
HY-10260BVandetanib (hydrochloride)
HY-10260SVandetanib-d6
HY-10260R-01Vandetanib (Standard)
HY-10260AVandetanib (trifluoroacetate)
HY-10260S2Vandetanib-13C6
HY-131414S5N-Demethyl vandetanib-d5
HY-151912S-01Picolinafen-d4 (4-Fluorophenyl-d4)
HY-132468SKeto Pioglitazone-d4 (M-III-d4)
HY-151892SGlimepiride-d4 (phenylethyl-α, α, β, β-d4) (cis/trans)

Alternative Products

CatalogName
AR-V06377-01Vandetanib-d4
sc-488983Hydroxy vandetanib-d4
AR-V06378-01N-Demethyl Vandetanib-d4
FV28668-01Vandetanib

Popular Products